Recent Advances and Future Perspectives in the Pharmacological Treatment of Infections

Introduction: is responsible for hospital outbreaks worldwide. Some isolates may show concomitant resistance to azoles, echinocandins, and polyenes, thereby possibly leaving clinicians with few therapeutic options.

Areas Covered: Antifungal agents both in early and in late phases of clinical development showing anti- activity.

Expert Opinion: The research on antifungal agents active against has made important steps forward in recent years: () the development of drugs with novel mechanisms of action, such as ibrexafungerp and fosmanogepix, could provide a valid option against strains resistant to one or more older antifungals, including pan-resistant strains; () rezafungin could allow once weekly administration of an active drug in the case of echinocandin-susceptible isolates, providing an effective outpatient treatment, while at the same time relieving selective pressure on novel classes; the development of oral formulations could allow step-down therapy and/or early discharge, or even to avoid hospitalization in mild or noninvasive diseases; () according to available data, these novel agents show a good safety profile and a low potential for drug-drug interactions.